Global Ophthalmics Partnering 2014-2019: Financial Deal Terms for Headline, Upfront and Royalty by Stage of Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Ophthalmics Partnering 2014-2019: Deal Trends, Players and Financials”
report has been added to ResearchAndMarkets.com’s
offering.

Global Ophthalmics Partnering 2014 to 2019 provides the full collection
of Ophthalmics disease deals signed between the world’s pharmaceutical
and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.

The report takes readers through the comprehensive Ophthalmics disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering
Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals,
where available listing by overall headline values, upfront payments,
milestones and royalties enabling readers to analyse and benchmark the
value of current deals.

The initial chapters of this report provide an orientation of
Ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Ophthalmics dealmaking
since 2014 covering trends by year, deal type, stage of development,
technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline
value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Ophthalmics deals since 2014.
Deals are listed by headline value. The chapter includes the top 25 most
active Ophthalmics dealmakers, together with a full listing of deals to
which they are a party. Where the deal has an agreement contract
published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Ophthalmics deals since 2014
where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities. Each
deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on
demand.

Chapter 6 provides a comprehensive directory of all Ophthalmics
partnering deals by specific Ophthalmics target announced since 2014.
The chapter is organized by specific Ophthalmics therapeutic target.
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of
all Ophthalmics partnering deals signed and announced since 2014. The
appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing
easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the
trends and activities in Ophthalmics partnering and dealmaking since
2014.

In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Ophthalmics technologies and products.

Report Scope

Global Ophthalmics Partnering 2014 to 2019 includes:

• Trends in Ophthalmics dealmaking in the biopharma industry since 2014
• Analysis of Ophthalmics deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Ophthalmics deal contract documents
• Comprehensive access to over 3500 Ophthalmics deal records
• The leading Ophthalmics deals by value since 2014
• Most active Ophthalmics dealmakers since 2014

Available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Ophthalmics dealmaking

2.1. Introduction

2.2. Ophthalmics partnering over the years

2.3. Ophthalmics partnering by deal type

2.4. Ophthalmics partnering by industry sector

2.5. Ophthalmics partnering by stage of development

2.6. Ophthalmics partnering by technology type

2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering

3.1. Introduction

3.2. Disclosed financials terms for Ophthalmics partnering

3.3. Ophthalmics partnering headline values

3.4. Ophthalmics deal upfront payments

3.5. Ophthalmics deal milestone payments

3.6. Ophthalmics royalty rates

Chapter 4 – Leading Ophthalmics deals and dealmakers

4.1. Introduction

4.2. Most active in Ophthalmics partnering

4.3. List of most active dealmakers in Ophthalmics

4.4. Top Ophthalmics deals by value

Chapter 5 – Ophthalmics contract document directory

5.1. Introduction

5.2. Ophthalmics partnering deals where contract document available

Chapter 6 – Ophthalmics dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Ophthalmics therapeutic target

Appendices

Appendix 1 – Directory of Ophthalmics deals by company A-Z 2014 to 2019

Appendix 2 – Directory of Ophthalmics deals by deal type 2014 to 2019

Appendix 3 – Directory of Ophthalmics deals by stage of development 2014
to 2019

Appendix 4 – Directory of Ophthalmics deals by technology type 2014 to
2019

For more information about this report visit https://www.researchandmarkets.com/research/jkk75z/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Optical
, Optical
Disorders Drugs